



# *papulosquamous disease:-*

- The term *squamous* refers to scaling that represents thick stratum corneum and thus implies an abnormal keratinization process
- lesions are characterized by sharply demarcated, red to violaceous papules and plaques that result from thickening of the epidermis or underlying dermal inflammation.





# Papulosquamous Diseases:-

- PSORIASIS
- Pityriasis rosea
- Lichen planus
- Seborrheic dermatitis
- Pityriasis rubra pilaris
- Secondary syphilis
- Miscellaneous mycosis fungoides,  
discoid lupus erythematosus, ichthyoses



# Psoriasis

## Definition

---

- Psoriasis is a common, chronic ,non-infectious , inflammtory skin disease.
- characterized by well-defined salmon-pink plaques bearing large adherent silvery scales-
- which affects the skin and joints .
- causes rapid skin cell reproduction resulting in red, dry patches of thickened skin



















# Incidence and aetiology:-

- The cause of PS still unknown
- 1-3%(under-estimate)
- F=M
- Any age (two peak of onset)
- Race:-any race; however, epidemiologic studies have shown a higher prevalence in western European and Scandinavian populations.





# Pathogenesis:-

- Exact cause is unknown
- Multi-factorial causes:-



# **1-Genetic factor:-**

-ps is a multi factorial disease with a complex genetic trait

-there are two inheritance mode:-

a-one has onset in younger age with family history of ps

b-the other has onset in late adulthood without family history of ps





- a child with one affected parent.....16%
- both parents.....50%
- non-psoriatic parents with affected child.....10%
- monozygotic twins.....70-
- dizygotic twins.....20%
- at least 9 loci have been identified(psors-1 to 9)



## Epidermal cell kinetics

-the growth fraction of basal cells is increased to almost 100%

compared with 30% in normal skin

-the epidermal turnover time is shortened to less than 10 days

compared with 30 10 60 days in normal skin





## **2-Inflammtory factors:-**

- Increase level of TNF**
- TNF receptors are upregulated**
- Increase level of interferon gamma**
- Increase level of interleukin 2 and 12**



# **3-Immunological factors:-**

- Psoriasis is fundamentally an inflammatory skin condition with reactive abnormal epidermal differentiation and hyperproliferation
- The inflammatory mechanisms are immune based and most likely initiated and maintained primarily by T cells in the dermis
- Antigen-presenting cells in the skin, such as Langerhans cells
- Tcells
- Auspits sign






# 4-Environmental factors:-

- Infection (streptococcal infection)
- Physical agents (eg, stress, alcoholism, smoking)
- Koebner phenomenon
- Drugs (lithium, anti-malarials, nsaid, beta-blockers)







# Histology

- parakeratosis(nuclei retained in the horny layer)
- irregular thickening of the epidermis over the rete ridges but thinning over dermal papillae
- epidermal polymorphonuclear leucocyte infiltrates (munro abscesses)
- dilated capillary loops in the dermal papillae
- T-lymph infiltrate in the upper dermis

# There are many types of psoriasis:-

- 1- **Plaque** :- Most common form of the disease
- 2- **Guttate** :- Appears as small red spots on the skin
- 3- **Inverse** :- Occurs in armpits, groin and skin folds
- 4- **Pustular** :- sterile small pustules, surrounded by red skin
- 5- **Erythrodermic** :- Intense redness over large areas
- 6- **Psoriatic arthritis** :-





# **Psoriasis can occur on any part of the body:-**

- Scalp psoriasis**
- Genital psoriasis**
- Around eyes, ears, mouth and nose**
- On the hands and feet**
- Psoriasis of the nails**



# **1-plaque psoriasis(psoriasis vulgaris) :-**

- the most common**
- characterized by round-to-oval red plaques distributed over extensor body surfaces and the scalp**
- up to 10-20% of patients with plaque psoriasis may evolve into more severe disease, such as pustular or erythrodermic psoriasis**



# cardinal features of plaque psoriasis:-

- 1- **Plaques:** Psoriasis manifests as elevated lesions that vary in size from one to several centimeters
  - The number of lesions may range from few to many at any given time
  - The plaques are irregular to oval and are most often located on the scalp, trunk, and limbs, with a predilection for extensor surfaces such as the elbows and knees
  - Fissuring within plaques can occur when lesions are present over joint lines or on the palms and soles
  - **Well-circumscribed margins:** Psoriatic plaques are well defined and have sharply demarcated boundaries



-Psoriatic plaques occasionally appear to be immediately encircled by a paler peripheral zone referred to as the halo or ring of Woronof

**2-** Red color: The color of psoriatic lesions is a very distinctive rich, full, red color

**3-** Scale: Psoriatic plaques typically have a dry, thin, silvery-white or micaceous scale;. Removing the scale reveals a smooth, red, glossy membrane with tiny punctate bleeding points. These points represent bleeding from enlarged dermal capillaries after removal of the overlying suprapapillary epithelium. This phenomenon is known as the Auspitz sign

**4-** Symmetry: Psoriatic plaques tend to be symmetrically distributed over the body.













## **2-Psoriasis, Guttate:-**

- Small, droplike, 1-10 mm in diameter, salmon- pink papules, usually with a fine scale
- Younger than 30 years
- Upper respiratory infection secondary to group A beta-hemolytic streptococci
- On the trunk and the proximal extremities
- Resolution within few months











# **3-ERYTHRODERMIC PSORIASIS:-**

- **Scaly erythematous lesions, involving 90% or more of the cutaneous surface**
- **hair may shed; nails may become ridged and thickened**
- **Few typical psoriatic plaques**
- **Unwell, fever, leucocytosis**
- **excessive of body heat and hypothermia**
- **increase cut blood flow**
- **Increase per-cut loss of water, protein and iron**
- **Increase per-cut permeability**









## **4-Psoriasis, Pustular:-**

- uncommon form of psoriasis
- pustules on an erythematous background
- psoriasis vulgaris may be present before, during, or after
- pustular psoriasis may be classified into several types

### **1-generalized type(von Zumbusch variant):**

- generalized erythema studded with interfollicular pustules
- fever, tachypneic, tachycardic
- absolute lymphopenia with polymorph nuclear leukocytosis up to 40,000/ $\mu$ L

### **2-Localized form (palms and soles)**




# Causes of pustular ps:-

- 1- Withdrawal of systemic steroids
- 2- Drugs, including salicylates,, lithium, phenylbutazone,, hydroxychloroquine,, interferon
- 3- Strong, irritating topicals, including tar, anthralin, steroids under occlusion, and zinc pyrithione in shampoo
- 4- Infections
- 5- Sunlight or phototherapy
- 6- Cholestatic jaundice
- 7- Hypocalcemia
- 8- Idiopathic in many patients













# 5-Psoriasis inversus(sebopsoriasis):-

- Over body folds
- The erythema and scales are very similar to that seen in seborrhoeic dermatitis









## **6-Psoriatic Arthritis:-**

- Psoriatic arthritis is a chronic inflammatory arthritis that is commonly associated with psoriasis
- 5% of patients with psoriasis develop psoriatic arthritis
- most commonly a seronegative oligoarthritis
- Asymmetric oligoarthritis occurs in as many as 70% of patients with psoriatic arthritis
- DIP joint involvement occurs in approximately 5-10% of patients with psoriatic arthritis
- Arthritis mutilans is a rare form of psoriatic arthritis occurring in 5% of patients with psoriatic arthritis
- Spondylitis occurs in about 5% of patients with psoriatic arthritis and is often asymptomatic



# **7-Psoriatic nail:-**

- Psoriatic nail disease occurs in 10-55% of all patients with psoriasis
- Less than 5% of psoriatic nail disease cases occur in patients without other cutaneous findings
- Nail changes are seen in 53-86% of patients with psoriatic arthritis
- Oil drop or salmon patch/nail bed
- Pitting
- Subungual hyperkeratosis
- Onycholysis
- Beau lines



# Differential diagnosis:-

- Bowes Disease
- Cutaneous T-Cell Lymphoma-
- Drug Eruptions-
- Erythema Annulare Centrifugum-
- Extramammary Paget Disease-
- Lichen Planus-
- Lichen Simplex Chronicus-
- Lupus Erythematosus, Discoid-
- Lupus Erythematosus, Subacute Cutaneous
- Nummular Dermatitis
- Parapsoriasis-
- Pityriasis Rosea-
- Pityriasis Rubra Pilaris-
- Seborrheic Dermatitis-
- Syphilis-
- Tine Corporis-



# **Lab Studies:-**

- Skin biopsy**
- others**



# Treatment of psoriasis

- What influences therapy choice?
  - Clinical type and severity of psoriasis (eg, mild vs moderate-to-severe), assessed by Psoriasis Area and Severity Index (PASI)
  - Response to previous treatment
  - Therapeutic options
  - Patient preference
- The “1-2-3” step approach is no longer generally accepted for disease more than mild in severity
  - Level 1: Topical agents—do not work
  - Level 2: “Phototherapy”—difficult; not always available
  - Level 3: Systemic therapy
- Risk in relation to benefit must be evaluated



# Topical Agents

- Initial therapeutic choice for mild-to-moderate psoriasis
  - Emollients
  - Keratolytics (salicylic acid, lactic acid, urea)
  - Coal tar
  - Anthralin
  - Vitamin D<sub>3</sub> analogues (calcipotriene)
  - Corticosteroids
  - Retinoids (tazarotene, acitretin)
- Compliance can be difficult due to amount of time required to apply topicals 2 to 4 times/day

# Phototherapy

- Used to treat moderate-to-severe psoriasis
- Phototherapy causes death of T cells in the skin
  - Natural sunlight
  - Ultraviolet (UV) B light
  - UVB light + coal tar (Goeckerman treatment)
    - Best therapeutic index for moderate-to-severe disease
  - UVB light + anthralin + coal tar (Ingram regimen)
  - Usually 3 treatments/week for 2 to 3 months is needed
  - Accessibility to a light box facility and compliance necessary



# Uva Light with psoralen (PUVA)

- Psoralen is a drug that causes a toxic reaction to skin lymphocytes when it is activated by UVA light
- Psoralen can be given systemically or topically
- Effective treatment—longest remissions of any treatment available
- Adverse effects
  - Nausea, burning, pruritus
  - Risk of cancer with cumulative use—both squamous cell carcinoma and melanoma
    - >160 cumulative treatments

# Methotrexate

- Folic acid metabolite
  - Blocks deoxyribonucleic acid synthesis, inhibits cell proliferation
- Dose
  - Start at about 15 mg/week; maximum 30 mg/week
  - Can also be given intramuscularly
- Adverse effects
  - Headache, nausea, bone marrow suppression
  - Cumulative dose predictive of liver toxicity
    - Prospectively identify risk factors for liver disease
    - Guidelines recommend liver biopsy after 1.5 g
    - Teratogenic in men and women



# Acitretin: Oral Retinoid

- Frequently used in combination with topical agents, systemic therapies, and UV light
- Less effective as monotherapy for plaque psoriasis
- Plaque psoriasis dose
  - Start at 10 to 25 mg/day
- Adverse effects (fewest dose-related adverse effects)
  - Peeling/dry skin, alopecia, muscle pain
  - Lipid abnormalities
- Teratogenic: avoid pregnancy

# Cyclosporine

- Reserved for severe, recalcitrant disease
- Inhibits the proliferation of activated T cells
- Dose: 4 mg/kg/day, not to exceed 5 mg/kg/day
  - Tapering slowly may improve remission
- Use not recommended for >1 year
  - Renal toxicity
- Patients relapse 2 to 4 months after discontinuing
- Adverse effects
  - Immunosuppression: infections, possible malignancy
  - Hirsutism, gingival hyperplasia, muscle pain, infection
  - Serious: hypertension, renal failure



# Biologic Therapies Currently Approved for the treatment of psoriasis

Alefacept

Efalizumab

Etanercept

# **Alefacept (Amevive) :-**

- Is the first biologic agent approved by the FDA for the treatment of psoriasis**
- It works by blocking T cell activation and proliferation by binding to CD2 receptors on T cells**
- This stops the T cells from releasing cytokines, which is the primary cause of the inflammation**
- 7.5 mg by intravenous injection or 15 mg by intramuscular injection once weekly for 12 weeks**
- S/E:-dizziness, cough, nausea, itching, muscle aches, chills, injection site pain and injection site redness and swelling**
  - Infections**




# Efalizumab (Raptiv)

- Recombinant humanized IgG1-kappa isotype monoclonal antibody
- Anti-CD11a antibody
- Down-regulates (decreases) surface expression of CD11a by 75-85% at psoriasis doses
- Initial dose: 0.7 mg/kg SC. Subsequent doses: 1 mg/kg/wk SC
  
- S/E:    -headache, chills, fever, nausea, vomiting  
          -thrombocytopenia  
          -may increase infection risk

# **Etanercept (enbril):-**

- This molecule serves as an exogenous TNF receptor and prevents excess TNF from binding to cell-bound receptors**
- 50mg SC given twice weekly for 3 mo, then 50 mg SC qwk**
- Contraindications:-**
  - sepsis, active infection, concurrent live vaccination**
- S/E:-**
  - injection site reactions (most common)**
  - upper respiratory tract infections**





***Adalimumab (Humira):***  
***Infliximab (Remicade):***  
***Ustekinumab (Stelara):***



# **Lichen Planus:-**

- Background:**
- Lichen planus (LP) is a pruritic, papular eruption characterized by its violaceous color; polygonal shape; and, sometimes, fine scale**
- It is most commonly found on the flexor surfaces of the upper extremities, on the genitalia, and on the mucous membranes.**



# **Epidemiology:-**

- Approximately 1% of all new patients seen at health care clinics**
- Rare in children**
- F=M**
- No racial predispositions have been noted**
- LP can occur at any age but two thirds of patients are aged 30-60 years**


# **Pathophysiology:-**

- The cause of LP is unknown
- LP may be a cell-mediated immune response of unknown origin
- LP may be found with other diseases of altered immunity like ulcerative colitis, alopecia areata, vitiligo, dermatomyositis
- An association is noted between LP and hepatitis C virus infection, chronic active hepatitis, and primary biliary cirrhosis
- Familial cases
- Drug may induce lichenoid reaction like thiazide, antimalarials, propranolol

# **Clinical features:-**

- **Most cases are insidious**
- **The initial lesion is usually located on the flexor surface of the limbs**
- **After a week or more, a generalized eruption develops with maximal spreading within 2-16 weeks-**
- **Pruritus is common but varies in severity**
- **Oral lesions may be asymptomatic or have a burning sensation**
- **In more than 50% of patients with cutaneous disease, the lesions resolve within 6 months, and 85% of cases subside within 18 months**



- 
- **The papules are violaceous, shiny, and polygonal; varying in size from 1 mm to greater than 1 cm in diameter**
  - **They can be discrete or arranged in groups of lines or Circles**
  - **Characteristic fine, white lines, called Wickham stria, are often found on the papules**
  - **Oral lesions are classified as reticular, plaquelike, atrophic, papular, erosive, and bullous**
  - **Ulcerated oral lesions may have a higher incidence of malignant transformation**
  - **Genital involvement is common in men with cutaneous disease**
  - **Vulvar involvement can range from reticulate papules to severe erosions**

# Variations in LP:-

## 1-Hypertrophic LP:-

-These extremely pruritic lesions are most often found on the extensor surfaces of the lower extremities, especially around the ankles

## 2-Atrophic LP:-

-is characterized by a few lesions, which are often the resolution of annular or hypertrophic lesions

## 3-Erosive LP

## 4-Follicular LP:-

-keratotic papules that may coalesce into plaques

-A scarring alopecia may result

## **5-Annular LP:-**

-Annular lesions with an atrophic center can be found on the buccal mucosa and the male genitalia

## **6-Vesicular and bullous LP:-**

-develop on the lower limbs or in the mouth from preexisting LP lesions

## **7-Actinic LP:-**

-Africa, the Middle East, and India

-mildly pruritic eruption

-characterized by nummular patches with a hypopigmented zone surrounding a hyperpigmented center

## **8-LP pigmentosus:-**

-common in persons with darker-pigmented skin

-usually appears on face and neck



# **LP and nail:-**


- **In 10% of patients**
- **nail plate thinning causes longitudinal grooving and ridging**
- **subungual hyperkeratosis, onycholysis**
- **Rarely, the matrix can be permanently destroyed with prominent pterygium formation**
- **twenty-nail dystrophy**









































# **DIFFERENTIALS:-**

- **Graft Versus Host Disease**
- **Lichen Nitidus**
- **Lichen Simplex Chronicus**
- **Pityriasis Rosea**
- **Psoriasis, Guttate**
- **Psoriasis, Plaque**
- **Syphilis**
- **Tine Corporis**

# TREATMENT

- self-limited disease that usually resolves within 8-12 months
- Anti-histamine
- topical steroids, particularly class I or II ointments
- systemic steroids for symptom control and possibly more rapid resolution
- Oral acitretin
- Photo-therapy
- Others







# Pityriasis Rosea

## **Definition:-**

- Acute mild inflammatory exanthem.
- Characterized by the development of erythematous scaly macules on the trunk.

## **Epidemiology:-**

- In children and young adult
- Increased incidence in spring and autumn
- PR has been estimated to account for 2% of dermatologic outpatient visits
- PR is more common in women than in men



# **Pathophysiology:-**

- PR considered to be a viral exanthem**
- Immunologic data suggest a viral etiology**
- Families and close contacts**
- A single outbreak tends to elicit lifelong immunity**
- Human herpesvirus (HHV)-7 and HHV-6**
- PR-like drug eruptions may be difficult to distinguish from non-drug-induced cases**
- Captopril, metronidazole, isotretinoin, penicillamine, bismuth, gold, barbiturates, and omeprazole.**

# **CLINICAL FEATURES:-**

- **Begins with a solitary macule that heralds the eruption(herald spot/patch )**
- **Usually a salmon-colored macule**
- **Over a few days it become a patch with a collarette of fine scale just inside the well-demarcated border**
- **Within the next 1-2 weeks, a generalized exanthem usually appears**
- **Bilateral and symmetric macules with a collarette scale oriented with their long axes along cleavage lines**
- **Tends to resolve over the next 6 weeks**
- **Pruritus is common, usually of mild-to-moderate severity**
- **Over trunk and proximal limbs**



# **Atypical form of PR:-**

- Occurs in 20% of patients
- Inverse PR
- Unilateral variant
- Papular PR
- Erythema multiforme-like
- Purpuric PR



















# **DIFFERENTIALS:-**

- **Lichen Planus**
- **Nummular Dermatitis**
- **Pityriasis Lichenoides**
- **Psoriasis, Guttate**
- **Seborrheic Dermatitis**
- **Syphilis**
- **Tine Corporis**



# **TREATMENT**

- Reassurance that the rash will resolve**
- Relief of pruritus**
- Topical menthol-phenol lotion**
- Oral antihistamines**
- Topical steroids**
- Systemic steroids**
- Ultraviolet B (UV-B) light therapy**